- Home
- BROG vs MNPR Comparison
BROG vs MNPR Comparison
Compare BROG & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- MNPR
- Stock Information
- Founded
- BROG 2019
- MNPR 2014
- Country
- BROG United Arab Emirates
- MNPR United States
- Employees
- BROG N/A
- MNPR N/A
- Industry
- BROG Integrated oil Companies
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- MNPR Health Care
- Exchange
- BROG Nasdaq
- MNPR Nasdaq
- Market Cap
- BROG 114.0M
- MNPR 95.5M
- IPO Year
- BROG N/A
- MNPR 2019
- Fundamental
- Price
- BROG $1.26
- MNPR $19.63
- Analyst Decision
- BROG
- MNPR Strong Buy
- Analyst Count
- BROG 0
- MNPR 3
- Target Price
- BROG N/A
- MNPR $27.33
- AVG Volume (30 Days)
- BROG 20.5K
- MNPR 486.0K
- Earning Date
- BROG 11-29-2024
- MNPR 11-08-2024
- Dividend Yield
- BROG N/A
- MNPR N/A
- EPS Growth
- BROG N/A
- MNPR N/A
- EPS
- BROG N/A
- MNPR N/A
- Revenue
- BROG $105,695,648.00
- MNPR N/A
- Revenue This Year
- BROG N/A
- MNPR N/A
- Revenue Next Year
- BROG N/A
- MNPR N/A
- P/E Ratio
- BROG N/A
- MNPR N/A
- Revenue Growth
- BROG 29.62
- MNPR N/A
- 52 Week Low
- BROG $0.80
- MNPR $1.37
- 52 Week High
- BROG $6.66
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- BROG 39.41
- MNPR 62.94
- Support Level
- BROG $1.33
- MNPR $16.26
- Resistance Level
- BROG $1.47
- MNPR $21.18
- Average True Range (ATR)
- BROG 0.17
- MNPR 1.87
- MACD
- BROG -0.04
- MNPR -0.13
- Stochastic Oscillator
- BROG 14.17
- MNPR 76.74
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.